Photo taken from the-scientist.com
Jul 10, 2024, 10:54
HEROS 2.0 trial using CAR T-cells targeting HER2 protein has shown safety and clinical benefit – St. Baldrick’s Foundation
St. Baldrick’s Foundation shared on LinkedIn:
“Exciting news on the horizon for sarcoma patients from researchers at Baylor College of Medicine! The latest HEROS 2.0 trial using CAR T-cells targeting HER2 protein has shown safety and clinical benefit, with 50% of patients seeing positive results. With continued research and multiple infusions, we’re seeing huge potential for long-term cancer-free outcomes.
Learn more about this research that was partially funded by St. Baldrick’s.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 20, 2024, 18:43
Dec 20, 2024, 18:34
Dec 20, 2024, 17:52
Dec 20, 2024, 17:31
Dec 20, 2024, 17:31